Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis
Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis

NCT01065727

CompletedNA

Sponsor: Rennes University Hospital

Conditions: Multiple Sclerosis

Interventions: mitoxantrone - immunomodulator, natalizumab

Countries: France

Cost-effectiveness study of 2 disease-modifying therapies (natalizumab versus mitoxantrone followed by immunomodulator) in the management of aggressive remitting multiple sclerosis

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Patients with remitting multiple sclerosis according to mac Donald criteria
* aggressive remitting multiple sclerosis according to following criteria:
* 2 or less disabling relapse during the 12 months before inclusion
* 1 or more
* EDSS between 2 and 5
* aged less or equal to 40 years old for the women
* effective contraception

Exclusion Criteria:

* patients less than 18 years old
Locations (2)
  • Brest, France
  • Rennes, France